Company Overview of Emerillon Therapeutics Inc.
Emerillon Therapeutics, Inc., a biotechnology company, engages in the discovery and development of genomics-based drugs for infectious diseases. The company, through its recombinant congenic strains (RCS) mouse platform technology, discovers and develops drugs for human complex diseases. Its RCS mouse platform focuses on identifying drug targets in the fields of pain, atherosclerosis, osteoporosis, and epilepsy. Emerillon Therapeutics also offers contract services, such as mutation detection using dHPLC, mouse genotyping, and speed congenesis. The company was founded in 2003 and is based in Montréal, Canada.
416 de Maisonneuve West
Montréal, QC H3A 1L2
Founded in 2003
Key Executives for Emerillon Therapeutics Inc.
Similar Private Companies By Industry
|2007262 Ontario, Inc.||Americas|
|2056273 Ontario, Inc.||Americas|
|AB BioPharma Inc.||Americas|
|AbCelex Technologies Inc.||Americas|
|AbCellera Biologics Inc.||Americas|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
To contact Emerillon Therapeutics Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.